USFDA issues Form 483 with 4 observations to Aurobindo Pharma

“We have been issued a Form 483 with four observations [which] are procedural in nature,” Aurobindo said.

781
USFDA Form 483
USFDA Form 483

Last Updated on October 9, 2024 by The Health Master

The U.S. Food and Drug Administration (USFDA) has issued a Form 483 with four observations to Aurobindo Pharma after inspecting the company’s (Unit XIV) active pharmaceutical ingredient manufacturing facility in Andhra Pradesh.

The API non-antibiotic manufacturing facility in Paravada Industrial Area, Anakapalli district, was inspected from May 15-19.

“We have been issued a Form 483 with four observations [which] are procedural in nature,” Aurobindo said.

The company said it will respond within the stipulated timelines and work closely with regulator to close the observations at the earliest.

On Friday, Aurobindo shares closed 1.64% lower at ₹589.45 each on the BSE.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news